273 related articles for article (PubMed ID: 33507917)
21. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma.
Chen Y; Lin X; Zou X; Qian Y; Liu Y; Wang R; Wang X; Yu X; Liu C; Cheng H
BMC Gastroenterol; 2023 Apr; 23(1):113. PubMed ID: 37024802
[TBL] [Abstract][Full Text] [Related]
22. Development and validation of a novel glycolysis-related risk signature for predicting survival in pancreatic adenocarcinoma.
Li A; Hou S; Chen J; Jiang Y
Clin Chim Acta; 2021 Jul; 518():156-161. PubMed ID: 33775699
[TBL] [Abstract][Full Text] [Related]
23. GNG7 and ADCY1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma through bioinformatic-based analyses.
Zhang Y; Yang J; Wang X; Li X
Sci Rep; 2021 Oct; 11(1):20441. PubMed ID: 34650124
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of E2F Transcription Factor Expression in Pancreatic Adenocarcinoma.
Luo L; Zhang G; Wu T; Wu G
Med Sci Monit; 2021 Nov; 27():e933443. PubMed ID: 34799547
[TBL] [Abstract][Full Text] [Related]
25. Identification of an extracellular vesicle-related gene signature in the prediction of pancreatic cancer clinical prognosis.
Xu D; Wang Y; Zhou K; Wu J; Zhang Z; Zhang J; Yu Z; Liu L; Liu X; Li B; Zheng J
Biosci Rep; 2020 Dec; 40(12):. PubMed ID: 33169793
[TBL] [Abstract][Full Text] [Related]
26. PLAGL1 is associated with prognosis and cell proliferation in pancreatic adenocarcinoma.
Liang X; Fu Z; Tang L; Zheng M; Chen D; Liu A; Shi L; Yang L; Shao C; Dong X
BMC Gastroenterol; 2023 Jan; 23(1):2. PubMed ID: 36600208
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of m5C regulatory gene expression in pancreatic adenocarcinoma.
Yu X; Zhang Q; Gao F; Zhang M; Zheng Q; He Y; Guo W
Sci Rep; 2021 Sep; 11(1):17529. PubMed ID: 34471186
[TBL] [Abstract][Full Text] [Related]
28. Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma.
Chen B; Hu C; Jiang L; Xiang Z; Zuo Z; Lin Y; Liu C
Int Immunopharmacol; 2021 Mar; 92():107359. PubMed ID: 33465729
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of leukemia inhibitory factor and its receptor in pancreatic adenocarcinoma.
Wang D; Liu K; Yang Y; Wang T; Rao Q; Guo W; Zhang Z
Future Oncol; 2020 Jan; 16(3):4461-4473. PubMed ID: 31854204
[TBL] [Abstract][Full Text] [Related]
30. LACTB, a novel epigenetic silenced tumor suppressor, inhibits colorectal cancer progression by attenuating MDM2-mediated p53 ubiquitination and degradation.
Zeng K; Chen X; Hu X; Liu X; Xu T; Sun H; Pan Y; He B; Wang S
Oncogene; 2018 Oct; 37(41):5534-5551. PubMed ID: 29899406
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive Analysis of m6A RNA Methylation Regulators and the Immune Microenvironment to Aid Immunotherapy in Pancreatic Cancer.
Guo Y; Wang R; Li J; Song Y; Min J; Zhao T; Hua L; Shi J; Zhang C; Ma P; Yang C; Zhu L; Gan D; Li S; Liu X; Su H
Front Immunol; 2021; 12():769425. PubMed ID: 34804059
[TBL] [Abstract][Full Text] [Related]
32. Identification of a 4-miRNA signature as a potential prognostic biomarker for pancreatic adenocarcinoma.
Wang ZX; Deng TX; Ma Z
J Cell Biochem; 2019 Oct; 120(10):16416-16426. PubMed ID: 31297864
[TBL] [Abstract][Full Text] [Related]
33. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
[TBL] [Abstract][Full Text] [Related]
34. EIF2Ss, a Novel c-Myc-Correlated Gene Family, is Associated with Poor Prognosis and Immune Infiltration in Pancreatic Adenocarcinoma.
Cao Z; Jing Y; Cheng C; Wang F; Guan M; Zhang K; Jiao J; Ruan L; Chen Z
Front Biosci (Landmark Ed); 2024 Mar; 29(3):119. PubMed ID: 38538250
[TBL] [Abstract][Full Text] [Related]
35. Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development.
Huang X; Zhang G; Tang T; Liang T
Mol Cancer; 2021 Mar; 20(1):44. PubMed ID: 33648511
[TBL] [Abstract][Full Text] [Related]
36. Weighted Gene Co-Expression Network Analysis Reveals Six Hub Genes Involved in and Tight Junction Function in Pancreatic Adenocarcinoma and their Potential Use in Prognosis.
Xia WX; Zhang LH; Liu YW
Genet Test Mol Biomarkers; 2019 Dec; 23(12):829-836. PubMed ID: 31821092
[No Abstract] [Full Text] [Related]
37. Development of an autophagy-related signature in pancreatic adenocarcinoma.
Yue P; Zhu C; Gao Y; Li Y; Wang Q; Zhang K; Gao S; Shi Y; Wu Y; Wang B; Xie J; Meng X
Biomed Pharmacother; 2020 Jun; 126():110080. PubMed ID: 32203889
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of CBX3 in Pancreatic Adenocarcinoma Promotes Cell Cycle Transition-Associated Tumor Progression.
Chen LY; Cheng CS; Qu C; Wang P; Chen H; Meng ZQ; Chen Z
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29903985
[TBL] [Abstract][Full Text] [Related]
39. CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma.
Liu K; Li L; Han G
Front Endocrinol (Lausanne); 2023; 14():1226547. PubMed ID: 38333724
[TBL] [Abstract][Full Text] [Related]
40. Aberrant FAM64A mRNA expression is an independent predictor of poor survival in pancreatic cancer.
Jiao Y; Fu Z; Li Y; Zhang W; Liu Y
PLoS One; 2019; 14(1):e0211291. PubMed ID: 30695070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
